Diagnostic Performance of Ex Vivo Fluorescence Confocal Microscopy in the Assessment of Diagnostic Biopsies of the Prostate.
confocal microscopy
digital pathology
prostate cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Nov 2021
13 Nov 2021
Historique:
received:
09
10
2021
revised:
07
11
2021
accepted:
10
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
Fluorescence confocal microscopy (FCM) is a novel micro-imaging technique providing optical sections of examined tissue. The method has been well established for the diagnosis of tumors in dermatological specimens. We compare intraoperative diagnoses of the real-time application of FCM in pre-therapeutic prostate biopsies (35 patients, total number of biopsy specimens: n = 438) with the findings of conventional histology. Prostate carcinoma was reliably diagnosed in all patients. Depending on scan quality and experience of the examiner, smaller lesions of well differentiated carcinoma (ISUP1) could not be consistently differentiated from reactive changes. Furthermore, in some cases there was difficulty to distinguish ISUP grade 2 from ISUP grade 1 tumors. ISUP grades 3-5 were reliably detected in FCM. Despite some limitations, FCM seems to be an effective tool for the timely assessment of prostate biopsies enabling reliable diagnosis of prostate cancer in patients requiring therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Fluorescence confocal microscopy (FCM) is a novel micro-imaging technique providing optical sections of examined tissue. The method has been well established for the diagnosis of tumors in dermatological specimens.
METHODS
METHODS
We compare intraoperative diagnoses of the real-time application of FCM in pre-therapeutic prostate biopsies (35 patients, total number of biopsy specimens: n = 438) with the findings of conventional histology.
RESULTS
RESULTS
Prostate carcinoma was reliably diagnosed in all patients. Depending on scan quality and experience of the examiner, smaller lesions of well differentiated carcinoma (ISUP1) could not be consistently differentiated from reactive changes. Furthermore, in some cases there was difficulty to distinguish ISUP grade 2 from ISUP grade 1 tumors. ISUP grades 3-5 were reliably detected in FCM.
CONCLUSIONS
CONCLUSIONS
Despite some limitations, FCM seems to be an effective tool for the timely assessment of prostate biopsies enabling reliable diagnosis of prostate cancer in patients requiring therapy.
Identifiants
pubmed: 34830839
pii: cancers13225685
doi: 10.3390/cancers13225685
pmc: PMC8616222
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Br J Cancer. 2015 Jul 14;113(2):193-8
pubmed: 26125442
BJU Int. 2020 Sep;126(3):336-338
pubmed: 32401370
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Mod Pathol. 2014 Mar;27(3):460-71
pubmed: 24030744
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Nat Rev Urol. 2021 Feb;18(2):79-92
pubmed: 33328650
Eur Urol Oncol. 2021 Oct;4(5):784-791
pubmed: 32952095
J Clin Pathol. 2003 Mar;56(3):230-2
pubmed: 12610105
N Engl J Med. 2021 Sep 2;385(10):908-920
pubmed: 34237810
Nat Genet. 2018 May;50(5):682-692
pubmed: 29662167
JAMA. 2017 Jun 27;317(24):2532-2542
pubmed: 28655021
Mod Pathol. 2018 Jan;31(S1):S12-21
pubmed: 29297490
J Biomed Opt. 2009 May-Jun;14(3):034050
pubmed: 19566342
BJU Int. 2019 Sep;124(3):469-476
pubmed: 30908852
J Clin Invest. 2013 Nov;123(11):4918-22
pubmed: 24135135
Prostate. 2020 Jan;80(1):38-50
pubmed: 31584209
Prostate. 2019 Jun;79(8):920-928
pubmed: 30908670
Quant Imaging Med Surg. 2021 Apr;11(4):1322-1332
pubmed: 33816171
Int Braz J Urol. 2019 Jan-Feb;45(1):32-37
pubmed: 30521172
Nat Rev Urol. 2018 Apr;15(4):222-234
pubmed: 29460925
BJU Int. 2019 Jul;124(1):9-26
pubmed: 31206997
Nat Genet. 2015 Jul;47(7):736-45
pubmed: 26005866
Virchows Arch. 2020 Apr;476(4):511-520
pubmed: 31907606
Int Rev Cytol. 1967;21:141-202
pubmed: 5338238
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
Eur Urol. 2019 Mar;75(3):498-505
pubmed: 30181068
Am J Surg Pathol. 2017 Apr;41(4):e1-e7
pubmed: 28177964
Am J Surg Pathol. 2005 Sep;29(9):1228-42
pubmed: 16096414
Histopathology. 2013 Jan;62(2):247-56
pubmed: 23240715
JAMA Netw Open. 2020 Mar 2;3(3):e200476
pubmed: 32134465
Hum Pathol. 2010 Jun;41(6):781-93
pubmed: 20466122
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571